HC Wainwright Reiterates Buy Rating for Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $75.00 price target on the stock.

SLN has been the topic of several other reports. Morgan Stanley reaffirmed an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a research note on Tuesday, October 8th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Finally, Chardan Capital reissued a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Stock Up 0.2 %

Shares of Silence Therapeutics stock opened at $5.25 on Wednesday. The company’s fifty day simple moving average is $6.63 and its two-hundred day simple moving average is $13.94. Silence Therapeutics has a 12-month low of $4.82 and a 12-month high of $27.72. The firm has a market cap of $157.13 million, a PE ratio of -3.34 and a beta of 1.08.

Institutional Investors Weigh In On Silence Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new stake in Silence Therapeutics during the third quarter valued at about $56,000. Quarry LP bought a new stake in Silence Therapeutics during the 2nd quarter valued at approximately $114,000. GAMMA Investing LLC lifted its holdings in Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after purchasing an additional 5,233 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Silence Therapeutics in the 4th quarter worth approximately $69,000. Finally, Verition Fund Management LLC purchased a new stake in Silence Therapeutics during the 3rd quarter valued at approximately $207,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.